The aim of our study was to quantify and characterize immunophenotypes of TAMs and investigate whether PD-L1+ and IDO-1+ TAMs have prognostic value in primary cHL patients treated with standard chemo- and radiotherapy. The gene discussed is IDO1; the disease is classic Hodgkin lymphoma.